Board of Directors

Nationality: South African

Committee memberships: Clinical Performance and Sustainability Committee, Investment Committee (Chairperson), Nomination Committee (Chairperson)

Dr Edwin Hertzog was appointed as the non-executive Chairman of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as a Director of Mediclinic International Ltd from 1983 and as the Chairman from 1992. As a specialist anaesthetist, he was commissioned by the then Rembrandt group (now Remgro) in 1983 to undertake a feasibility study on the establishment of a private hospital group. Three years later, in 1986, Mediclinic International Ltd (then Medi-Clinic Corporation Ltd) was listed on the JSE Ltd (then Johannesburg Stock Exchange). He was appointed as the first Managing Director of Mediclinic International Ltd upon its establishment in 1983. He served as executive Chairman of Mediclinic from 1992 until August 2012 when he retired from his executive role but remained on the Board as non-executive Chairman. He also serves as the non-executive deputy Chairman of Remgro and is a past Chairman of the Council of Stellenbosch University.

Qualifications: Dr Hertzog holds an MBChB (Stellenbosch University); the FCA (SA) (Fellowship of the College of Anaesthetists of South Africa); and a PhD in Philosophy honoris causa (Stellenbosch University).    

Nationality: South African

Committee membership: Clinical Performance and Sustainability Committee, Investment Committee

Dr Ronnie van der Merwe is a specialist anaesthetist who worked in the medical insurance industry before joining the Company in 1999 as Clinical Manager. He established the Advanced Analytics, Clinical Information, Clinical Services and Health Information Management functions at Mediclinic, and subsequently served as the Group’s Chief Clinical Officer. He was appointed as an executive Director of Mediclinic International Ltd in 2010 up to the acquisition of Al Noor Hospitals Group plc. He was appointed as an executive Director and Chief Executive Officer of Mediclinic, with effect from 1 June 2018 and has also served on Spire’s Board of Directors as a non-executive Director from 24 May 2018.

Qualifications: Dr Van der Merwe holds an MBChB (Stellenbosch University); a DA (SA) (College of Anaesthetists of South Africa); the FCA (SA) (Fellowship of the College of Anaesthetists of South Africa); and completed the AMP (Harvard Business School).

Nationality: South African

Committee membership: Investment Committee    

Mr Jurgens Myburgh was appointed as an executive Director and Chief Financial Officer of the Company on 1 August 2016. Prior to joining Mediclinic, he served as Chief Financial Officer at Datatec Ltd, an international ICT group, and before that, as Executive Vice President of Investment Banking at The Standard Bank of South Africa Ltd.

Qualifications: Mr Myburgh holds a BComm Hons in Accounting (University of Johannesburg) and is a qualified Chartered Accountant registered with the South African Institute of Chartered Accountants.

Nationality: South African

Committee memberships: Audit and Risk Committee (Chairperson), Nomination Committee

Mr Desmond Smith was appointed as an independent non-executive Director of the Company on 15 February 2016 upon the successful combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd. Prior to the combination, he served as an independent non-executive Director of Mediclinic International Ltd from 2008 and as the lead independent Director from 2010. He currently holds the position of Chairman at the Reinsurance Group of America (South Africa) (“RGA”). He was the Chief Executive Officer of the Sanlam Group (“Sanlam”) from 1993–1997 and of RGA from 1999–2005. He was also Chairman of Sanlam from 2009–2017. During his career, he has served on various boards and was president of both the Actuarial Society of South Africa (1996) and the International Actuarial Association (2012).

Qualifications: Mr Smith holds a BSc (Stellenbosch University); has completed the International Senior Management Programme (Harvard Business School); and is a fellow of the Actuarial Society of South Africa.

Nationality: Emirati

Committee membership: Clinical Performance and Sustainability Committee

Dr Muhadditha Al Hashimi was appointed as an independent non-executive Director of the Company on 1 November 2017. She is also a member of the Board of Trustees and the Audit and Compliance Committee of the University of Sharjah, a member of the Board of Trustees of the UAE Nursing and Midwifery Council and the UAE Genetics Diseases Association. She is currently the Chairperson of Sharjah Private Education Authority, UAE. Prior to her current position, Dr Al Hashimi was the Campus Director of Higher Colleges of Technology Sharjah Women’s and Men’s Colleges in the UAE. In addition, Dr Al Hashimi held the position of Executive Dean of the Faculty of Health Sciences, Higher Colleges of Technology; Acting Deputy Vice-Chancellor of Academic Affairs at the Higher Colleges of Technology; Chief Executive Officer of the Mohammed Bin Rashid Al Maktoum Academic Medical Centre in Dubai; Chief Executive Officer of Dubai Healthcare City; and the Director of Education of the Harvard Medical School Dubai Centre.

Qualifications: Dr Al Hashimi holds a BS in Medical Technology (University of Minnesota); an MSc in Clinical Laboratory Services (University of Minnesota); and a DrPH in Public Health (University of Texas). 

Nationality: South African

Committee memberships: Investment Committee, Nomination Committee

Mr Jannie Durand* was appointed as a non-executive Director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as a non-executive Director of Mediclinic International Ltd from 2012. He joined the Rembrandt group in 1996 and in 2012 was appointed as the Chief Executive Officer of Remgro Ltd, which holds a 44.56% interest in the Company. In his current role, with more than 20 years’ experience in the investment industry, he acts as a non-executive Director of various companies, including Distell Group Ltd, RCL Foods Ltd and RMI Holdings Ltd.

Qualifications: Mr Durand holds a BAcc Hons in Accountancy (Stellenbosch University); an MPhil in Management Studies (Oxford University); and is a qualified Chartered Accountant registered with the South African Institute of Chartered Accountants.

* Mr Pieter Uys, the Head of Strategic Investment at Remgro Ltd, is appointed as the alternate to Mr Durand, effective 7 April 2016. Prior to joining Remgro Ltd, Mr Uys was a founding member and ultimately became the Chief Executive Officer of the Vodacom Group.    

Qualifications: Mr Uys holds an MEng in Electronic Engineering (Stellenbosch University) and an executive MBA (Stellenbosch University).

Nationality: British

Committee memberships: Audit and Risk Committee, Investment Committee    

Mr Alan Grieve was appointed as an independent non-executive Director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as an independent non-executive Director of Mediclinic International Ltd from 2012 and as a Director of Mediclinic Switzerland AG (now Hirslanden AG) from 2008–2012. He served as Chief Financial Officer of Reinet Investments Manager S.A. and Reinet Fund Manager S.A. from 2008–2011 and Chief Executive Officer from 2012 until he retired in 2014. He remains on the boards of both companies as a non-executive Director. He served as Company Secretary of Richemont, the Swiss luxury goods group, from 1998–2004 and as Director of Corporate Affairs from 2004–2014. Prior to joining Richemont’s predecessor companies in 1986, he worked with the international auditing firms now known as PricewaterhouseCoopers and EY.

Qualifications: Mr Grieve holds a BA Hons Business Administration (Heriot-Watt University) and is a member of the Institute of Chartered Accountants of Scotland.

Nationality: British

Committee membership: Clinical Performance and Sustainability Committee (Chairperson), Nomination Committee    

Dr Felicity Harvey was appointed as an independent non-executive Director of the Company on 3 October 2017. She serves as a Visiting Professor at the Institute of Global Health Innovation at Imperial College London; is a non-executive Director of Guy’s and St Thomas’ NHS Foundation Trust in London; a Trustee of Royal Trinity Hospice in London; and Chair of the World Health Organization Independent Oversight & Advisory Committee for Health Emergencies. Previously, she served as Director-General of Public and International Health at the UK Department of Health; Director of the UK Prime Minister’s Delivery Unit, then HM Treasury’s Performance and Reform Unit; Head of the Medicines, Pharmacy and Industry Group at the Department of Health; Director of Prison Health at Her Majesty’s Prison Service; Head of Quality Management at NHS Executive; and private Secretary to the Chief Medical Officer of the Department of Health for England. Dr Harvey was appointed CBE in 2008.

Qualifications: Dr Harvey holds an MB BS (St. Bartholomew’s Medical College, University of London); a PgDip in Clinical Microbiology (The Royal London Hospital College, University of London); an MBA (Henley Management College); and is an honorary fellow of the Royal College of Physicians and a fellow of the Faculty of Public Health.

Nationality: Irish

Committee memberships: Audit and Risk Committee, Clinical Performance and Sustainability Committee, Remuneration Committee

Mr Seamus Keating was appointed as an independent non-executive Director of the Company (then Al Noor Hospitals Group plc) on 5 June 2013 and continues to serve as a Director of the Company following the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016. He has over 20 years’ experience in the global technology sector in finance and operational roles, and was a main board Director of Logica plc from 2002–2012. He was Chief Financial Officer of Logica plc from 2002–2010 when he became Chief Executive Officer and head of its Benelux operations. Prior to his role at Logica plc, he worked for the Olivetti Group in senior finance roles in the United Kingdom and Italy. He served as non-executive Director and Chairman of the audit committee of Mouchel plc from November 2010–2012. He is currently Chairman of First Derivatives plc, a non-executive Director of BGL Group Ltd and a non-executive Director of Mi-pay Group plc.

Qualifications: Mr Keating is a fellow of the UK Chartered Institute of Management Accountants.    

Nationality: South African

Committee membership: Investment Committee

Mr Danie Meintjes served as the Chief Executive Officer of Mediclinic from 2010 up to his retirement on 1 June 2018, remaining on the Board as an executive Director until 31 July 2018. He currently serves as a non-executive Director, effective 1 August 2018, and as the designated non-executive Director for workforce engagement, effective 1 April 2019. He was appointed as an executive Director and Chief Executive of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as the Chief Executive Officer of Mediclinic International Ltd from 2010. He has served in various management positions in the Remgro group before joining Mediclinic in 1985 as the Hospital Manager of Mediclinic Sandton. He was appointed as a member of Mediclinic’s Executive Committee in 1995 and as a Director in 1996. He was seconded to serve as a senior executive of the Group’s operations in Dubai in 2006 and appointed as the Chief Executive Officer of Mediclinic Middle East in 2007. Mr Meintjes serves as a non-executive Director of Capitec Bank Holdings Ltd and Capitec Bank Ltd. He served as a non-executive Director of Spire Healthcare Group plc from 2015, a position from which he retired on 24 May 2018.

Qualifications: Mr Meintjes holds a BPL Hons in Industrial Psychology (University of the Free State) and completed the AMP (Harvard Business School).

Nationality: Swiss

Committee memberships: Nomination Committee, Remuneration Committee 

Dr Anja Oswald was appointed as an independent non-executive Director of the Company on 25 July 2018. She is the Chief Executive Officer of the Klinik Sonnenhalde, a well-established private clinic for psychiatry and psychotherapy with inpatients, day-care clinics and outpatients in Riehen, Switzerland, and is President of the Association of Private Hospitals in Basel. She is also a board member of Integrierte Psychiatrie Winterthur in Canton Zürich and of the Alliance for a Free Health Care System in Switzerland. Prior to this, she was Head of Medical and Pharmaceutical Services and Deputy Medical Officer in the Department of Health of the

Cantonal Government in Basel and a member of various cantonal, regional and national committees. Dr Oswald was also the Chief Executive Officer of a start-up company in the healthcare sector and worked several years as a Medical Doctor in different hospitals.

Qualifications: Dr Oswald holds an MD PhD specialising in Orthopaedic Surgery and Traumatology, as well as in Sports Medicine (University of Basel) and an executive MBA (University of Rochester-Berne). She passed the Board School at the International Centre of Corporate Governance of the University of St. Gallen.    

Nationality: South African

Committee memberships: Audit and Risk Committee, Remuneration Committee (Chairperson)

Mr Trevor Petersen was appointed as an independent non-executive Director of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as an independent non-executive Director of Mediclinic International Ltd from 2012. In 1996, he resigned as a Lecturer from the University of Cape Town to take up a partnership in the merged firm of PricewaterhouseCoopers Inc. He served as a partner of the national firm from 1997–2009 and as the partner-in-charge of Cape Town and as Chairman of the Western Cape region. He is an independent non-executive Director on the board of Media24 (Pty) Ltd (a subsidiary of Naspers Ltd) and is currently the managing trustee of the Woodside Village Trust. He has served professional membership associations such as the South African Institute of Chartered Accountants and was elected the Chairman of the National Body in 2006–2007.

Qualifications: Mr Petersen holds a BComm Hons in Accountancy (University of Cape Town) and is a qualified Chartered Accountant registered with the South African Institute of Chartered Accountants.